Why HPLC Is the Standard for Peptide Purity
HPLC (High-Performance Liquid Chromatography) is the primary analytical method used to measure peptide purity because it separates compounds physically based on their interaction with the chromatography column, producing a visual and quantitative record of every compound in the sample.For a research peptide, the HPLC trace provides:
1. Purity percentage — what fraction of the material is the desired compound
2. Identity confirmation — the main peak elutes at a characteristic retention time consistent with the compound's molecular properties
3. Impurity profiling — any additional peaks reveal contaminants, truncated sequences, or degradation products
When you see "99%+ purity" on a Phase 1 Peptides COA, that value is derived directly from HPLC peak area analysis.
---
Understanding the HPLC Chromatogram
An HPLC chromatogram is a graph with time (minutes) on the x-axis and UV absorbance signal (typically at 214 nm or 220 nm) on the y-axis. Each compound in the sample absorbs UV light and produces a peak.
The Main Peak
The largest peak in the chromatogram represents the primary compound — the research peptide itself. Key properties to evaluate:
Peak height and area: The area under the main peak, expressed as a percentage of total peak area in the run, is the purity percentage. If the main peak accounts for 99.4% of total area, the reported purity is 99.4%. Peak shape: A sharp, symmetric (Gaussian) peak is ideal. Asymmetric peaks — tailing on the right, or fronting on the left — can indicate overloading, poor column equilibration, or co-eluting species. Minor tailing is common in peptide analysis and acceptable within defined limits. Retention time: The time at which the main peak elutes — how long the compound takes to travel through the column — is characteristic of the compound's molecular structure. A retention time inconsistent with historical data for the compound can flag a mis-identification or degradation, though retention times are method-specific and only directly comparable within the same HPLC system and method.Impurity Peaks
Any peak other than the main compound peak is an impurity. Common impurity sources in synthetic peptides include:
- Truncated sequences: Incomplete chain assembly during synthesis; peptides shorter than the target by one or more amino acids
- Deletion sequences: Peptides missing a non-terminal amino acid in the middle of the sequence
- Deprotection artifacts: Side-product fragments from solid-phase synthesis chemistry
- Oxidized variants: Methionine-containing peptides are prone to Met sulfoxide formation; cysteine to disulfide
- Aggregates or dimers: Less common at typical HPLC analysis concentrations
A COA showing a single dominant peak with a purity ≥99% means the total contribution of all impurity peaks combined is ≤1% of peak area.
---
Common HPLC Methods for Peptides
Most research peptide COAs use reverse-phase HPLC (RP-HPLC) — the most widely applicable method for peptide purity analysis:
Column: C18 (octadecylsilane) bonded silica is standard. Some labs use C8 or phenyl columns for specific applications. Mobile phase: Typically a gradient from aqueous (water + 0.1% TFA or formic acid) to organic (acetonitrile + 0.1% TFA or formic acid). The gradient elutes peptides by increasing hydrophobic character. Detection: UV absorbance at 214 nm is standard for peptides because the peptide bond absorbs near this wavelength, making it applicable to virtually all peptides regardless of sequence. Some COAs report at 220 nm or 254 nm. Run time: Typically 10–30 minutes depending on the method. Short methods (10–15 min) are common in quality control settings.---
Reading the Purity Percentage
HPLC purity is calculated as:
> Purity (%) = (Main peak area / Total peak area) × 100
Where "total peak area" includes all peaks above the system integration threshold. This is called the area normalization method — it assumes all compounds have similar UV response factors, which is a reasonable approximation for peptide-to-peptide comparisons.
When Phase 1 Peptides reports "99%+ purity," this means the main compound peak accounts for at least 99% of total peak area in the COA-method HPLC analysis for that lot.
What HPLC Purity Does NOT Tell You
HPLC purity is a relative measurement. It quantifies the compound as a percentage of what was detected by UV absorption under the specific HPLC method. It does not:
- Directly measure absolute concentration (a separate assay is needed for that)
- Detect all possible impurities — UV-invisible compounds (those with very low UV absorption) may not appear in the trace
- Guarantee biological activity — purity is a chemical, not functional, measurement
For this reason, high-quality COAs pair HPLC purity with LC-MS identity confirmation, which provides direct molecular weight evidence for the compound's identity.
---
How to Evaluate a COA HPLC Trace
When reviewing a COA chromatogram:
1. Locate the main peak. It should be the dominant feature of the trace.
2. Check the purity percentage. Phase 1 Peptides specifies ≥99% for research-grade compounds.
3. Count any visible impurity peaks. Minor peaks <0.5% area each are typical in high-purity research materials.
4. Look at peak symmetry. A tailing factor <2 is generally acceptable.
5. Note the retention time. Compare to prior lots or the compound's known hydrophobicity — a very early or very late elution versus expectation warrants investigation.
6. Verify the baseline. A flat baseline between peaks indicates good separation. A rising or noisy baseline can indicate column degradation or sample matrix effects.
For a broader guide to reading all sections of a Certificate of Analysis — including LC-MS, residual solvent, and lot numbering — see Understanding Your Certificate of Analysis.
---
HPLC vs. LC-MS: Complementary, Not Interchangeable
| Analysis | What it confirms | What it misses |
| HPLC | Purity (% main compound) | Molecular identity (isomers may co-elute) |
| LC-MS | Molecular identity (mass confirmed) | Impurity quantity (LC-MS is less quantitative than HPLC area) |
The strongest COA documentation combines both: HPLC for purity quantification and LC-MS for molecular identity confirmation. This combination is what Phase 1 Peptides provides on its batch documentation.
---
---
Common Questions
Q: What does the purity percentage on an HPLC COA actually measure?HPLC purity is calculated as the area fraction of the main peak relative to all UV-absorbing peaks in the chromatogram. A result of 99.2% means the target peptide accounts for 99.2% of the total integrated UV signal. It does not directly measure mass — compounds with different extinction coefficients contribute differently to peak area. Non-UV-absorbing compounds (certain counterions, water) do not contribute to HPLC purity at all.
Q: Why can HPLC purity be ≥99% while the peptide still contains TFA counterion?TFA (trifluoroacetate) is a small organic acid that lacks a UV chromophore in the standard HPLC detection range. It does not produce a peak in the HPLC trace and therefore does not dilute the purity percentage. HPLC purity measures the peptide compound and its related impurities — not the counterion. TFA content is a separate mass measurement (typically 10–25% by mass for TFA salt form peptides) and is reported separately on COAs that include it. Both values can coexist without contradiction.
Q: What should a researcher look for in the baseline region of an HPLC chromatogram?A good baseline should be flat between peaks — there should be no rising slope, irregular noise, or broad humps that might indicate co-eluting impurities, column bleed, or sample matrix effects. A rising or noisy baseline can inflate peak areas or mask small impurity peaks. If the baseline before or after the main peak shows significant non-flatness, it may indicate that the reported purity calculation included baseline correction that should be examined more carefully.
Q: Why does peak symmetry matter when evaluating HPLC data?Peak symmetry — measured by the tailing factor or asymmetry factor — indicates whether the separation is clean and complete. A tailing factor >2 suggests the compound is eluting incompletely from the stationary phase, co-eluting with a structurally similar impurity, or experiencing column overloading. Highly asymmetric peaks can cause the peak integration algorithm to include impurity contributions in the main peak area, leading to artificially inflated purity estimates. A tailing factor <2 is the standard acceptability criterion in pharmaceutical HPLC.
Related Quality Resources
- Understanding Your Certificate of Analysis
- How to Verify a Research Peptide COA
- Lab Testing & Verified Purity
- Lyophilization Explained
- Peptide Concentration Calculations
- TFA Content & Salt Form Interpretation
- LC-MS Identity Confirmation — how mass spectrometry confirms molecular identity on a COA
- HPLC vs LC-MS: A Researcher's Comparison — how purity analysis and identity confirmation work together in peptide batch documentation
- Storage & Handling Best Practices
All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.